09:12 AM EDT, 04/22/2024 (MT Newswires) -- Adial Pharmaceuticals ( ADIL ) said Monday it has been granted a US patent covering the combination of its proprietary genetic diagnostic and its lead Investigational New Drug AD04 to treat alcohol use disorder and other drug dependencies.

"We have identified specific genotypes that have responded with clinically meaningful changes in drinking behavior compared to placebo in the AD04 post hoc analysis, which represents an addressable market of approximately $40 billion in the US alone," Chief Executive Cary Claiborne said.

Shares of Adial Pharmaceuticals ( ADIL ) were up 2.6% in recent Monday premarket activity.